መነሻ › የሳንባ መካከለኛ ሕዋስ በሽታዎች › ሚሺጋን
በሚሺጋን ለየሳንባ መካከለኛ ሕዋስ በሽታዎች የሚደረጉ ክሊኒካዊ ጥናቶች
ለየሳንባ መካከለኛ ሕዋስ በሽታዎች የሚደረጉ 16 ጥናቶች በሚሺጋን ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሚሺጋን ውስጥ ያሉ ከተሞች
Official study text (English)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 40 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07201922Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- Allen Park, Allen Park
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07473700A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Henry Ford Health, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 40 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Michigan - Michigan Medicine, Ann Arbor
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Ann Arbor
- Clinical Research Site, Detroit
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Corewell Health Beamont Troy Hospital, Troy
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT06855329Platform Clinical Study for Conquering Scleroderma
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT06328777Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Henry Ford Health, Detroit
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 21 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Corewell Health Grand Rapids Hospitals - Butterworth, Grand Rapids
- Beaumont Hospital, Royal Oak, Royal Oak
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT05943535A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Galderma Investigational Site # 8743, Ann Arbor
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ማርች 2026 · NCT07047690Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
- University of Michigan, Ann Arbor
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሜይ 2024 · NCT06397677ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።